Bayer confirms 2025 targets after solid start to the year
EBITDA before special items decreases to €4.08 billion (7.4%)
EBITDA before special items decreases to €4.08 billion (7.4%)
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
ekincare has raised a total funding of $22M since 2015 till date
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Rising demands and advancements in eye care drive growth
Subscribe To Our Newsletter & Stay Updated